-
2
-
-
69849083049
-
Assessment of fracture risk
-
Kanis JA, Johansson H, Oden A, McCloskey EV,. Assessment of fracture risk. Eur J Radiol 2009; 71: 392-7.
-
(2009)
Eur J Radiol
, vol.71
, pp. 392-397
-
-
Kanis, J.A.1
Johansson, H.2
Oden, A.3
McCloskey, E.V.4
-
3
-
-
79952782200
-
New drugs: Denosumab, dienogest/estradiol valerate, and polidocanol
-
Hussar DA, Stevenson T,. New drugs: denosumab, dienogest/estradiol valerate, and polidocanol. J Am Pharm Assoc 2010; 50: 658-62.
-
(2010)
J Am Pharm Assoc
, vol.50
, pp. 658-662
-
-
Hussar, D.A.1
Stevenson, T.2
-
4
-
-
63949085680
-
The impact of incident fractures on health-related quality of life: 5 years of data from the Canadian Multicentre Osteoporosis Study
-
Papaioannou A, Kennedy CC, Ioannidis G, et al., The impact of incident fractures on health-related quality of life: 5 years of data from the Canadian Multicentre Osteoporosis Study. Osteoporos Int 2009; 20: 703-14.
-
(2009)
Osteoporos Int
, vol.20
, pp. 703-714
-
-
Papaioannou, A.1
Kennedy, C.C.2
Ioannidis, G.3
-
5
-
-
22844443812
-
Risk factors associated with incident clinical vertebral and nonvertebral fractures in postmenopausal women: The Canadian Multicentre Osteoporosis Study (CaMos)
-
Papaioannou A, Joseph L, Ioannidis G, et al., Risk factors associated with incident clinical vertebral and nonvertebral fractures in postmenopausal women: the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos Int 2005; 16: 568-78.
-
(2005)
Osteoporos Int
, vol.16
, pp. 568-578
-
-
Papaioannou, A.1
Joseph, L.2
Ioannidis, G.3
-
6
-
-
34848845797
-
Vitamin D and its implications for musculoskeletal health in women: An update
-
Perez-Lopez FR,. Vitamin D and its implications for musculoskeletal health in women: an update. Maturitas 2007; 58: 117-37.
-
(2007)
Maturitas
, vol.58
, pp. 117-137
-
-
Perez-Lopez, F.R.1
-
7
-
-
84855517766
-
Denosumab (Prolia): A new option in the treatment of osteoporosis
-
Belavic JM,. Denosumab (Prolia): a new option in the treatment of osteoporosis. Nurse Pract 2011; 36: 11-2.
-
(2011)
Nurse Pract
, vol.36
, pp. 11-12
-
-
Belavic, J.M.1
-
8
-
-
46049097498
-
Canadian Consensus Conference on Osteoporosis, 2006 Update
-
Brown JP, Fortier M,. Canadian Consensus Conference on Osteoporosis, 2006 Update. J Obstet Gynec Canada 2006; 172: S95-112.
-
(2006)
J Obstet Gynec Canada
, vol.172
-
-
Brown, J.P.1
Fortier, M.2
-
9
-
-
0036782072
-
Discoveries, drugs and skeletal disorders
-
Goltzman D,. Discoveries, drugs and skeletal disorders. Nat Rev Drug Discov 2002; 1: 784-96.
-
(2002)
Nat Rev Drug Discov
, vol.1
, pp. 784-796
-
-
Goltzman, D.1
-
10
-
-
39349086278
-
Systematic review: Comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis
-
MacLean C, Newberry S, Maglione M, et al., Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 2008; 148: 197-213.
-
(2008)
Ann Intern Med
, vol.148
, pp. 197-213
-
-
MacLean, C.1
Newberry, S.2
Maglione, M.3
-
11
-
-
84869502087
-
-
Amgen Canada Inc, October
-
Prolia Product Monograph. Amgen Canada Inc, October 2011.
-
(2011)
Prolia Product Monograph
-
-
-
12
-
-
78650397541
-
Clinical development of anti-RANKL therapies for treatment and prevention of bone metastasis
-
Lipton A, Goessl C,. Clinical development of anti-RANKL therapies for treatment and prevention of bone metastasis. Bone 2011; 48: 96-9.
-
(2011)
Bone
, vol.48
, pp. 96-99
-
-
Lipton, A.1
Goessl, C.2
-
13
-
-
79953897155
-
Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass
-
Bone HG, Bolognese MA, Yuen CK, et al., Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 2011; 96: 972-80.
-
(2011)
J Clin Endocrinol Metab
, vol.96
, pp. 972-980
-
-
Bone, H.G.1
Bolognese, M.A.2
Yuen, C.K.3
-
14
-
-
78649680817
-
2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: Summary
-
Papaioannou A, Morin S, Cheung AM, et al., 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ Canadian Medical Association Journal 2010; 182: 1864-73.
-
(2010)
CMAJ Canadian Medical Association Journal
, vol.182
, pp. 1864-1873
-
-
Papaioannou, A.1
Morin, S.2
Cheung, A.M.3
-
16
-
-
84869490878
-
Ontario's strategy paves the way for better care across Canada
-
Osteoporosis Society of Canada
-
Osteoporosis Society of Canada. Ontario's strategy paves the way for better care across Canada. Osteoporos Update 2005; 9: 6-7.
-
(2005)
Osteoporos Update
, vol.9
, pp. 6-7
-
-
-
17
-
-
77954536223
-
Population-based Canadian hip fracture rates with international comparisons
-
Leslie WD, O'Donnell S, Lagace C, et al., Population-based Canadian hip fracture rates with international comparisons. Osteoporos Int 2010; 21: 1317-22.
-
(2010)
Osteoporos Int
, vol.21
, pp. 1317-1322
-
-
Leslie, W.D.1
O'Donnell, S.2
Lagace, C.3
-
18
-
-
77956375686
-
Impact of prevalent fractures on quality of life: Baseline results from the global longitudinal study of osteoporosis in women
-
Adachi JD, Adami S, Gehlbach S, et al., Impact of prevalent fractures on quality of life: baseline results from the global longitudinal study of osteoporosis in women. Mayo Clin Proc 2010; 85: 806-13.
-
(2010)
Mayo Clin Proc
, vol.85
, pp. 806-813
-
-
Adachi, J.D.1
Adami, S.2
Gehlbach, S.3
-
19
-
-
77749270855
-
Effect of osteoporosis treatment on mortality: A meta-analysis
-
Bolland MJ, Grey AB, Gamble GD, Reid IR,. Effect of osteoporosis treatment on mortality: a meta-analysis. J Clin Endocrinol Metab 2010; 95: 1174-81.
-
(2010)
J Clin Endocrinol Metab
, vol.95
, pp. 1174-1181
-
-
Bolland, M.J.1
Grey, A.B.2
Gamble, G.D.3
Reid, I.R.4
-
20
-
-
79952032073
-
The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients
-
Hiligsmann M, Rabenda V, Bruyere O, Reginster JY,. The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients. Health Policy 2010; 96: 170-7.
-
(2010)
Health Policy
, vol.96
, pp. 170-177
-
-
Hiligsmann, M.1
Rabenda, V.2
Bruyere, O.3
Reginster, J.Y.4
-
21
-
-
36649033348
-
The care gap in diagnosis and treatment of women with a fragility fracture
-
Bessette L, Ste-Marie LG, Jean S, et al., The care gap in diagnosis and treatment of women with a fragility fracture. Osteoporos Int 2008; 19: 79-86.
-
(2008)
Osteoporos Int
, vol.19
, pp. 79-86
-
-
Bessette, L.1
Ste-Marie, L.G.2
Jean, S.3
-
22
-
-
52449112052
-
Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial
-
Miller PD, Bolognese MA, Lewiecki EM, et al., Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 2008; 43: 222-9.
-
(2008)
Bone
, vol.43
, pp. 222-229
-
-
Miller, P.D.1
Bolognese, M.A.2
Lewiecki, E.M.3
-
23
-
-
0036440553
-
2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada
-
Brown JP, Josse RG,. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002; 167: S1-34.
-
(2002)
CMAJ
, vol.167
-
-
Brown, J.P.1
Josse, R.G.2
-
24
-
-
0141723284
-
Reduced bone formation and increased bone resorption: Rational targets for the treatment of osteoporosis
-
Seeman E,. Reduced bone formation and increased bone resorption: rational targets for the treatment of osteoporosis. Osteoporos Int 2003; 14 (Suppl. 3): S2-8.
-
(2003)
Osteoporos Int
, vol.14
, Issue.SUPPL. 3
-
-
Seeman, E.1
-
25
-
-
0034455103
-
Birth and death of bone cells: Basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis
-
Manolagas SC,. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 2000; 21: 115-37.
-
(2000)
Endocr Rev
, vol.21
, pp. 115-137
-
-
Manolagas, S.C.1
-
26
-
-
33646396235
-
Estrogen deficiency and bone loss: An inflammatory tale
-
Weitzmann MN, Pacifici R,. Estrogen deficiency and bone loss: an inflammatory tale. J Clin Invest 2006; 116: 1186-94.
-
(2006)
J Clin Invest
, vol.116
, pp. 1186-1194
-
-
Weitzmann, M.N.1
Pacifici, R.2
-
28
-
-
79952087103
-
Primary hyperparathyroidism: Update on presentation, diagnosis, and management in primary care
-
Pallan S, Khan A,. Primary hyperparathyroidism: Update on presentation, diagnosis, and management in primary care. Can Fam Physician 2011; 57: 184-9.
-
(2011)
Can Fam Physician
, vol.57
, pp. 184-189
-
-
Pallan, S.1
Khan, A.2
-
29
-
-
84882467756
-
Pharmacologic Mechanisms of Therapeutics: Parathyroid Hormone
-
Bilezikian J.P. Raisz L.G. Martin T.J. eds. Amsterdam, The Netherlands: Elsevier
-
Hanley DA, Watson PM, Hodsman AB, Dempster DM,. Pharmacologic Mechanisms of Therapeutics: Parathyroid Hormone. In:, Bilezikian JP, Raisz LG, Martin TJ, eds. Principles of Bone Biology. Amsterdam, The Netherlands: Elsevier, 2008:: 1661-95.
-
(2008)
Principles of Bone Biology
, pp. 1661-1695
-
-
Hanley, D.A.1
Watson, P.M.2
Hodsman, A.B.3
Dempster, D.M.4
-
30
-
-
70349573790
-
Clinical update on teriparatide
-
File E, Deal C,. Clinical update on teriparatide. Curr Rheumatol Rep 2009; 11: 169-76.
-
(2009)
Curr Rheumatol Rep
, vol.11
, pp. 169-176
-
-
File, E.1
Deal, C.2
-
31
-
-
79952698455
-
Denosumab and bisphosphonates: Different mechanisms of action and effects
-
Baron R, Ferrari S, Russell RG,. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 2011; 48: 677-92.
-
(2011)
Bone
, vol.48
, pp. 677-692
-
-
Baron, R.1
Ferrari, S.2
Russell, R.G.3
-
32
-
-
79959412176
-
Osteoblasts in osteoporosis: Past, emerging, and future anabolic targets
-
Marie PJ, Kassem M,. Osteoblasts in osteoporosis: past, emerging, and future anabolic targets. Eur J Endocrinol 2011; 165: 1-10.
-
(2011)
Eur J Endocrinol
, vol.165
, pp. 1-10
-
-
Marie, P.J.1
Kassem, M.2
-
33
-
-
0036677983
-
Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women
-
Cranney Ae G, Willan A, Griffith L, et al., Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 2002; 23: 508-16.
-
(2002)
Endocr Rev
, vol.23
, pp. 508-516
-
-
Cranney Ae, G.1
Willan, A.2
Griffith, L.3
-
34
-
-
43049109229
-
Mechanisms of action of bisphosphonates: Similarities and differences and their potential influence on clinical efficacy
-
Russell RGG, Watts NB, Ebetino FH, Rogers MJ,. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008; 19: 733-59.
-
(2008)
Osteoporos Int
, vol.19
, pp. 733-759
-
-
Russell, R.G.G.1
Watts, N.B.2
Ebetino, F.H.3
Rogers, M.J.4
-
35
-
-
0033065233
-
Bisphosphonates: From the laboratory to the clinic and back again
-
Russell RG, Rogers MJ,. Bisphosphonates: from the laboratory to the clinic and back again. Bone 1999; 25: 97-106.
-
(1999)
Bone
, vol.25
, pp. 97-106
-
-
Russell, R.G.1
Rogers, M.J.2
-
36
-
-
0033581212
-
Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators
-
Ettinger B, Black DM, Mitlak BH, et al., Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999; 282: 637-45.
-
(1999)
JAMA
, vol.282
, pp. 637-645
-
-
Ettinger, B.1
Black, D.M.2
Mitlak, B.H.3
-
38
-
-
75949111995
-
Raloxifene inhibits bone loss and improves bone strength through an OPG-independent mechanism
-
Yan MZ, Xu Y, Gong YX, et al., Raloxifene inhibits bone loss and improves bone strength through an OPG-independent mechanism. Endocrine 2010; 37: 55-61.
-
(2010)
Endocrine
, vol.37
, pp. 55-61
-
-
Yan, M.Z.1
Xu, Y.2
Gong, Y.X.3
-
39
-
-
0037042498
-
Treatment of postmenopausal osteoporosis
-
Delmas PD,. Treatment of postmenopausal osteoporosis. Lancet 2002; 359: 2018-26.
-
(2002)
Lancet
, vol.359
, pp. 2018-2026
-
-
Delmas, P.D.1
-
40
-
-
0029907556
-
Effects of hormone therapy on bone mineral density: Results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI
-
PEPI Trial Writing Group
-
PEPI Trial Writing Group. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI. JAMA 1996; 276: 1389-96.
-
(1996)
JAMA
, vol.276
, pp. 1389-1396
-
-
-
41
-
-
78650651667
-
Denosumab: A review of its use in the treatment of postmenopausal osteoporosis
-
Moen MD, Keam SJ,. Denosumab: a review of its use in the treatment of postmenopausal osteoporosis. Drugs Aging 2011; 28: 63-82.
-
(2011)
Drugs Aging
, vol.28
, pp. 63-82
-
-
Moen, M.D.1
Keam, S.J.2
-
42
-
-
77952744612
-
Treatment of osteoporosis with denosumab
-
Lewiecki EM,. Treatment of osteoporosis with denosumab. Maturitas 2010; 66: 182-6.
-
(2010)
Maturitas
, vol.66
, pp. 182-186
-
-
Lewiecki, E.M.1
-
43
-
-
84863116813
-
Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension
-
Papapoulos S, Chapurlat R, Libanati C, et al., Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension. J Bone Miner Res 2012; 27: 694-701.
-
(2012)
J Bone Miner Res
, vol.27
, pp. 694-701
-
-
Papapoulos, S.1
Chapurlat, R.2
Libanati, C.3
-
44
-
-
58149099647
-
Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: A randomized, blinded, phase 3 trial
-
Brown JP, Prince RL, Deal C, et al., Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 2009; 24: 153-61.
-
(2009)
J Bone Miner Res
, vol.24
, pp. 153-161
-
-
Brown, J.P.1
Prince, R.L.2
Deal, C.3
-
45
-
-
77953715717
-
Microarchitectural deterioration of cortical and trabecular bone: Differing effects of denosumab and alendronate
-
Seeman E, Delmas PD, Hanley DA, et al., Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res 2010; 25: 1886-94.
-
(2010)
J Bone Miner Res
, vol.25
, pp. 1886-1894
-
-
Seeman, E.1
Delmas, P.D.2
Hanley, D.A.3
-
46
-
-
84862246228
-
Data from extension trials: Denosumab and zoledronic acid
-
Dore RK,. Data from extension trials: denosumab and zoledronic acid. Curr Osteoporos Rep 2012; 10: 16-21.
-
(2012)
Curr Osteoporos Rep
, vol.10
, pp. 16-21
-
-
Dore, R.K.1
-
47
-
-
77953454405
-
Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy
-
Kendler DL, Roux C, Benhamou CL, et al., Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 2010; 25: 72-81.
-
(2010)
J Bone Miner Res
, vol.25
, pp. 72-81
-
-
Kendler, D.L.1
Roux, C.2
Benhamou, C.L.3
-
48
-
-
69049083492
-
Denosumab for prevention of fractures in postmenopausal women with osteoporosis. [Erratum appears in N Engl J Med. 2009 Nov 5;361(19):1914]
-
Cummings SR, San Martin J, McClung MR, et al., Denosumab for prevention of fractures in postmenopausal women with osteoporosis. [Erratum appears in N Engl J Med. 2009 Nov 5;361(19):1914]. N Engl J Med 2009; 361: 756-65.
-
(2009)
N Engl J Med
, vol.361
, pp. 756-765
-
-
Cummings, S.R.1
San Martin, J.2
McClung, M.R.3
-
49
-
-
84869487593
-
-
Merck Frosst Canada Ltd
-
Fosamax Product Monograph. Merck Frosst Canada Ltd, 2010.
-
(2010)
Fosamax Product Monograph
-
-
-
50
-
-
0004851872
-
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group
-
Black DM, Cummings SR, Karpf DB, et al., Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348: 1535-41.
-
(1996)
Lancet
, vol.348
, pp. 1535-1541
-
-
Black, D.M.1
Cummings, S.R.2
Karpf, D.B.3
-
51
-
-
0032583492
-
Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial
-
Cummings SR, Black DM, Thompson DE, et al., Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280: 2077-82.
-
(1998)
JAMA
, vol.280
, pp. 2077-2082
-
-
Cummings, S.R.1
Black, D.M.2
Thompson, D.E.3
-
52
-
-
84869492962
-
-
Warner Chilcott Canada Co
-
Actonel Product Monograph. Warner Chilcott Canada Co., 2011.
-
(2011)
Actonel Product Monograph
-
-
-
53
-
-
0033552255
-
Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group
-
Harris ST, Watts NB, Genant HK, et al., Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999; 282: 1344-52.
-
(1999)
JAMA
, vol.282
, pp. 1344-1352
-
-
Harris, S.T.1
Watts, N.B.2
Genant, H.K.3
-
54
-
-
0035253489
-
Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group
-
McClung MR, Geusens P, Miller PD, et al., Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001; 344: 333-40.
-
(2001)
N Engl J Med
, vol.344
, pp. 333-340
-
-
McClung, M.R.1
Geusens, P.2
Miller, P.D.3
-
55
-
-
84869498216
-
-
Novartis Pharmaceuticals Canada Inc
-
Aclasta Product Monograph. Novartis Pharmaceuticals Canada Inc., 2011.
-
(2011)
Aclasta Product Monograph
-
-
-
56
-
-
34247866550
-
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
-
Black DM, Delmas PD, Eastell R, et al., Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356: 1809-22.
-
(2007)
N Engl J Med
, vol.356
, pp. 1809-1822
-
-
Black, D.M.1
Delmas, P.D.2
Eastell, R.3
-
57
-
-
0037125379
-
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial
-
Rossouw JE, Anderson GL, Prentice RL, et al., Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33.
-
(2002)
JAMA
, vol.288
, pp. 321-333
-
-
Rossouw, J.E.1
Anderson, G.L.2
Prentice, R.L.3
-
59
-
-
0035837553
-
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis
-
Neer RM, Arnaud CD, Zanchetta JR, et al., Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434-41.
-
(2001)
N Engl J Med
, vol.344
, pp. 1434-1441
-
-
Neer, R.M.1
Arnaud, C.D.2
Zanchetta, J.R.3
|